ClinicalTrials.gg

Program

Semaglutide

Also written as “semaglutide”, “Oral semaglutide” and “Semaglutide 2.4 mg”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Obesity · Diabetes Mellitus · Non-alcoholic Fatty Liver Disease · Alzheimer Disease, led by 11 companies.

Furthest: phase 4, since Jul 11, 2018163 company-led studies, 15 open or runningNext primary completion: Dec 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novo Nordisk1518 open or runningphase 4since Jul 11, 2018Jun 11, 2008Dec 13, 2026phase 1 · NCT07225816
CSPC Pharmaceutical Group20 open or runningphase 3since Nov 30, 2023Nov 30, 2023none ahead
Hangzhou Jiuyuan Gene Engineering21 open or runningphase 3since Feb 20, 2023Feb 20, 2023none ahead
chengdu-brilliant-pharmaceutical-co-ltd11 open or runningphase 3since Mar 18, 2024Mar 18, 2024none ahead
Geropharm10 open or runningphase 1since Jul 4, 2024Jul 4, 2024none ahead
Gila Therapeutics11 open or runningphase 4since Apr 17, 2026Apr 17, 2026May 2027phase 4 · NCT07728383
Korea United Pharm.11 open or runningphase 1since Oct 28, 2026Oct 28, 2026Nov 1, 2027phase 1 · NCT07935200
Qilu Pharmaceutical11 open or runningphase 3since Jul 11, 2023Jul 11, 2023none ahead
Shanghai World Leader Pharmaceutical11 open or runningphase 1since Jan 28, 2026Jan 28, 2026none ahead
Sino Biopharmaceutical10 open or runningphase 3since Dec 13, 2024Dec 13, 2024none ahead
Vivani Medical11 open or runningphase 1since Feb 10, 2026Feb 10, 2026Dec 2026phase 1 · NCT07430059

Also a collaborator on its studies: celerion and avance-clinical-pty-ltd.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 46 studies since Oct 16, 2020.

  1. Aug 22, 2024Phase 4 study in ObesityNovo Nordisk · NCT06571383 · 500 enrolled · United States, Belgium, Canada and more
  2. Sep 12, 2024Phase 3 study in Weight ManagementCSPC Pharmaceutical Group · NCT06604624 · 462 enrolled · China
  3. Oct 7, 2024Phase 3 study in ObesityHangzhou Jiuyuan Gene Engineering · NCT06633783 · 370 planned · China
  4. Oct 13, 2024Phase 1 study in Healthy Volunteers Type 2 DiabetesNovo Nordisk · NCT06642584 · 90 enrolled · Canada
  5. Dec 13, 2024Sino Biopharmaceutical's first study: phase 3 study in ObesityNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT06738979 · 408 enrolled · China
  6. Nov 5, 2025Phase 1 study in ObesityNovo Nordisk · NCT07225816 · 71 planned · United States
  7. Nov 27, 2025Phase 3 study in Diabetes Mellitus, Type 2Novo Nordisk · NCT07271251 · 267 enrolled · Japan
  8. Jan 28, 2026Shanghai World Leader Pharmaceutical's first study: phase 1 study in OverweightNew to Shanghai World Leader PharmaceuticalShanghai World Leader Pharmaceutical · NCT07465965 · 60 planned · United States
  9. Feb 10, 2026Vivani Medical's first study: phase 1 study in ObesityNew to Vivani MedicalVivani Medical · NCT07430059 · 20 planned
  10. Apr 17, 2026Gila Therapeutics's first study: phase 4 study in ObesityNew to Gila TherapeuticsGila Therapeutics · NCT07728383 · 40 planned · United States
  11. Aug 13, 2026Phase 3 study in OverweightNovo Nordisk · NCT07770841 · 450 planned · United States, Belgium, Bulgaria and more
  12. Sep 22, 2026Phase 1 study in ObesityNovo Nordisk · NCT07845578 · 60 planned · Austria
  13. Oct 21, 2026Phase 4 study in Renal Insufficiency, ChronicNovo Nordisk · NCT07900438 · 300 planned · China
  14. Oct 28, 2026Korea United Pharm.'s first study: phase 1 study in BioequivalenceNew to Korea United Pharm.Korea United Pharm. · NCT07935200 · 44 planned · South Korea

Ahead

  1. Dec 2026Primary completion: phase 1 study in ObesityVivani Medical · NCT07430059
  2. Dec 13, 2026Primary completion: phase 1 study in ObesityNovo Nordisk · NCT07225816
  3. May 2027Primary completion: phase 4 study in ObesityGila Therapeutics · NCT07728383
  4. Sep 11, 2027Primary completion: phase 1 study in ObesityNovo Nordisk · NCT07845578

TargetBeta

GLP1R →read by rule
“A glucagon-like peptide-1 (GLP-1) receptor agonist that is 94% homologous to human GLP-1 (7-37), with antihyperglycemic and appetite regulating activities”NCIt, by rule
“Glucagon-like peptide 1 receptor agonist”ChEMBL 37, by rule

Other programs on GLP1R

ProgramCompanyFurthest phaseStudies
LiraglutideruleNovo Nordiskphase 4116
TirzepatideruleEli Lillyphase 472
dulaglutideruleEli Lillyphase 447
orforglipronruleEli Lillyphase 350
survodutideBoehringer Ingelheimphase 335
zenagamtideNovo Nordiskphase 335
retatrutideruleEli Lillyphase 333
mazdutideruleInnovent Biologicsphase 327
bofanglutideruleGan & Lee Pharmaceuticalsphase 325
berobenatidePfizerphase 323
SafiglipronJiangsu HengRui Medicinephase 319
efpeglenatideruleHanmi Pharmaceuticalphase 313

Studies

The newest 60 of 163 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07935200Bioequivalence · South Korea1Not yet recruitingKorea United Pharm.Nov 1, 202744
NCT07900438Renal Insufficiency, Chronic · China4RecruitingNovo NordiskDec 20, 2029300
NCT07845578Obesity · Austria1Not yet recruitingNovo NordiskSep 11, 202760
NCT07770841Overweight · United States, Belgium, Bulgaria and more3RecruitingNovo NordiskFeb 22, 2028450
NCT07728383Obesity · United States4RecruitingGila TherapeuticsMay 202740
NCT07430059Obesity1Not yet recruitingVivani MedicalDec 202620
NCT07465965Overweight · United States1RecruitingShanghai World Leader PharmaceuticalAug 21, 202660
NCT07271251Diabetes Mellitus, Type 2 · Japan3CompletedNovo NordiskJun 29, 2026267
NCT07225816Obesity · United States1RecruitingNovo NordiskDec 13, 202671
NCT06738979Obesity · China3CompletedSino BiopharmaceuticalMar 7, 2026408
NCT06642584Healthy Volunteers Type 2 Diabetes · Canada1CompletedNovo NordiskJul 10, 202590
NCT06633783Obesity · China3Not yet recruitingHangzhou Jiuyuan Gene EngineeringMay 30, 2026370
NCT06604624Weight Management · China3CompletedCSPC Pharmaceutical GroupAug 27, 2025462
NCT06571383Obesity · United States, Belgium, Canada and more4Active, not recruitingNovo NordiskNov 15, 2028500
NCT06497049Pharmacokinetics · Russian Federation1CompletedGeropharmMay 5, 2024120
NCT06409130Alcohol-related Liver Disease · United States, Australia, Bulgaria and more2CompletedNovo NordiskNov 21, 2025270
NCT06339086Diabetes Mellitus, Type 23Not yet recruitingchengdu-brilliant-pharmaceutical-co-ltdAug 30, 2025478
NCT06267092Overweight · Germany1CompletedNovo NordiskApr 7, 2025164
NCT06161844Diabetes Mellitus, Type 2 · China3CompletedCSPC Pharmaceutical GroupMay 14, 2025506
NCT06097390Healthy Participants · Canada1CompletedNovo NordiskFeb 22, 2024121
NCT06083675Diabetes Mellitus, Type 2 · United States, Brazil, Bulgaria and more3WithdrawnNovo NordiskJan 24, 20250
NCT06041217Overweight · China, Taiwan3CompletedNovo NordiskApr 2, 2025242
NCT05996874Healthy Participants · Germany1CompletedNovo NordiskApr 18, 2024121
NCT05950516Diabetes Mellitus, Type 2 · China3Not yet recruitingQilu PharmaceuticalNov 24, 2024478
NCT05891496Alzheimer Disease · United States, Canada, Denmark and more3CompletedNovo NordiskAug 19, 202423
NCT05890976Overweight · China3CompletedNovo NordiskJan 16, 2025200
NCT05813912Diabetes Mellitus, Type 2 · Czechia, Malaysia, Poland and more3CompletedNovo NordiskApr 14, 2025148
NCT05784402Healthy Participants · United States, Canada1CompletedNovo NordiskFeb 23, 2024264
NCT05816057Diabetes Mellitus, Type 2 · China3CompletedHangzhou Jiuyuan Gene EngineeringJul 25, 2023476
NCT05726227Obesity · United States, Austria, Belgium and more3Active, not recruitingNovo NordiskOct 15, 2025212
NCT05689099Diabetes Mellitus, Type 2 · United States1CompletedNovo NordiskMay 30, 202320
NCT05649137Obesity · United States, Bulgaria, Canada and more3CompletedNovo NordiskOct 28, 2024512
NCT05646706Obesity · United States, Bulgaria, Canada and more3CompletedNovo NordiskOct 30, 20241,407
NCT05579249Obesity · United States4CompletedNovo NordiskNov 27, 2024500
NCT05564117Overweight · United States, Canada, Germany and more3CompletedNovo NordiskApr 18, 2024307
NCT05533632Diabetes Mellitus, Type 2 · Chile4CompletedNovo NordiskJan 18, 2024104
NCT05514535Diabetes Mellitus, Type 2 · United States, Czechia, Greece and more3CompletedNovo NordiskMar 5, 2025573
NCT05486065Diabetes Mellitus, Type 2 · United States, Greece, Hungary and more2CompletedNovo NordiskOct 12, 2023245
NCT05478252Diabetes Mellitus, Type 2 · United States, Canada, Poland and more3CompletedNovo NordiskAug 9, 2023388
NCT05444153Diabetes Mellitus, Type 23WithdrawnNovo NordiskOct 2, 20240
NCT05429593Healthy Volunteers · Germany1CompletedNovo NordiskMar 10, 2023152
NCT05352815Diabetes Mellitus, Type 2 · United States, Australia, Belgium and more3CompletedNovo NordiskMar 19, 20241,291
NCT05227196Diabetes Mellitus, Type 2 · United States, Canada1CompletedNovo NordiskJun 28, 2023546
NCT05232708Diabetes Mellitus · United Kingdom1CompletedNovo NordiskAug 30, 202218
NCT05132088Overweight · Japan, South Korea3CompletedNovo NordiskJul 11, 2023201
NCT05064735Obesity · United States, Canada, Colombia and more3CompletedNovo NordiskJul 24, 2023407
NCT05040971Obesity · Canada, Denmark, Finland and more3CompletedNovo NordiskJan 6, 2023207
NCT05035095Obesity · United States, Canada, Denmark and more3CompletedNovo NordiskMar 24, 2023667
NCT05035082Diabetes Mellitus, Type 2 · United States4CompletedNovo NordiskJun 18, 20251,018
NCT04998136Obesity · South Korea, Thailand3CompletedNovo NordiskOct 16, 2023150
NCT04940078Obesity · Canada, Denmark1CompletedNovo NordiskJan 19, 202240
NCT04916470Diabetes Mellitus · United States, Argentina, Austria and more3CompletedNovo NordiskOct 11, 2023617
NCT04865770Diabetes Mellitus, Type 2 · United States, Canada, Denmark and more3CompletedNovo NordiskNov 21, 2024106
NCT04822181Non-alcoholic Fatty Liver Disease · United States, Argentina, Australia and more3Active, not recruitingNovo NordiskApr 25, 20291,205
NCT04817644Diabetes Mellitus, Type 2 · United States1CompletedNovo NordiskMay 26, 202314
NCT04788511Obesity · United States, Argentina, Australia and more3CompletedNovo NordiskApr 18, 2023529
NCT04777409Early Alzheimer´s Disease · United States, Argentina, Australia and more3CompletedNovo NordiskSep 15, 20251,840
NCT04777396Alzheimer Disease · United States, Argentina, Australia and more3CompletedNovo NordiskSep 16, 20251,840
NCT04707469Diabetes Mellitus, Type 2 · United States, Australia, Bulgaria and more3CompletedNovo NordiskMar 7, 20231,606
NCT04596631Diabetes Mellitus, Type 2 · United States, Australia, Austria and more3CompletedNovo NordiskApr 29, 2025132

How it is read

Names in the registry

  • “semaglutide”, 83 entries
  • “Semaglutide”, 66 entries
  • “Oral semaglutide”, 11 entries
  • “Semaglutide 2.4 mg”, 3 entries
  • “Semaglutide J”, 3 entries

Codes read as this program: UI112, HD1916.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.